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Extracellular nucleotides stimulate proliferation in
MCF-7 breast cancer cells via P2-purinoceptors
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Summary Nucleotides such as ATP can act as extracellular effector molecules by interaction with specific cellular receptors known as P2-
purinoceptors. Recently, we cloned the human P2U purinoceptor from osteoclastoma and demonstrated its expression in skeletal tissues. In
the current study we have investigated the expression of P2U purinoceptors in human breast tumour cell lines and examined functional effects
of extracellular nucleotides on these cells. By reverse transcription-linked polymerase chain reaction (RT-PCR) the expression of mRNA for
P2U purinoceptors was demonstrated in four human breast cancer cell lines, Hs578T, MCF-7, SK-Br3 and T47-D. In MCF-7 cells, extracellular
ATP (1-100 gM) elevated intracellular free calcium concentration [Ca2+]i, indicating that these cells express functional P2-purinoceptors. UTP
elevated [Ca2+]i in an identical manner to ATP, whereas 2-methylthioATP was completely ineffective, and ADP only partially effective. This
pharmacological profile suggests that the P2U subtype may be the only P2-purinoceptor expressed by these cells. The functional significance
of P2U purinoceptor expression by MCF-7 cells was investigated by analysing the effects of extracellular ATP on cell proliferation. The slowly
hydrolysed analogue of ATP, ATPyS (which was also shown to elevate [Ca2+]i), induced proliferation of MCF-7 cells when added daily to
serum-free cultures over a period of 3 days. ATPyS-induced proliferation was demonstrated by three separate methods, detection by
scintillation counting of [3H]thymidine incorporation, immunocytochemical detection of 5-bromo-2-deoxyuridine incorporation and direct
counting of cell numbers. These data suggest that ATP, possibly released at sites of tissue injury or inflammation, may be capable of growth
factor action in promotion of tumour proliferation or progression.
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It is now well recognized that ATP and other nucleotides act as
extracellular signalling molecules to induce a variety of cellular
responses by interacting with specific cell-surface receptors
known as P2-purinoceptors (Gordon, 1986; Harden et al, 1995).
The diversity of cellular responses to ATP and other nucleotides
(Dubyak and Fedan, 1990; El-Moatassim et al, 1992) suggested
the involvement of multiple receptor types, and the classification
ofreceptor subtypes was originally inferred from pharmacological
responses to nucleotides in vitro (Burnstock and Kennedy, 1985).
Two major classes of P2-purinoceptors have been delineated: P2X
purinoceptors, which are ligand-gated ion channels, and P2Y
purinoceptors, which are G-protein-coupled receptors. This classi-
fication has recently been expanded (Abbracchio and Burnstock,
1994; Barnard et al, 1994) to accommodate the results of cloning
studies that revealed the existence of multiple subclasses of P2y
purinoceptors (Lustig et al, 1993; Webb et al, 1993; Parr et al,
1994). Activation of the two major subclasses of G-protein-
coupled receptors, P2Y(P2Y1) andP2U(P2Y2)' results in phospholipase
C-catalysed hydrolysis of phosphatidylinositol 4,5-bisphosphate
and consequent inositol 1,4,5-trisphosphate-mediated release of
calcium from intracellular stores (Boarder et al, 1995). A large
number of studies have demonstrated the existence of G-protein-
coupled P2-purinoceptors on tumour cell lines (Dubyak, 1986;
Dubyak et al, 1988; Gonzalez et al, 1989a,b; El-Moatassim et
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al, 1992; Torres-Marquez et al, 1993), but the implications of
purinergic stimulation for the growth and development of cancer
have not been thoroughly investigated, as studies ofgrowth control
of tumours have tended to focus on peptide growth factors and
hormones. A number of investigators have demonstrated
inhibition of cancer cell growth by ATP at high concentrations
(100 gM to 1 mM) (Weisman et al, 1988; Rapaport, 1990; Dubyak
andEl-Moatassim, 1993). At lowerconcentrations, however, mito-
genic actions of extracellular ATP, mediated by P2-purinoceptors,
have been reported in numerous cell types, including aortic
smooth muscle cells (Wang et al, 1992), mesangial cells (Schulze-
Lohoff et al, 1992; Ishikawa et al, 1994) and the human ovarian
cancer cell lines, OVCAR-3 (Popper and Batra, 1993) and SKOV-
3 (Batra and Fadeel, 1994). ATP has also been shown to act as a
co-mitogen in concert with other growth factors to enhance
cellular proliferation in transformed mouse fibroblasts and epider-
moid carcinoma A431 cells (Huang et al, 1989) and aortic smooth
muscle (Wang et al, 1992).
We have recently cloned the human P2U purinoceptor from a
human giant cell tumour (osteoclastoma) (Bowler et al, 1995), The
presence ofP2U purinoceptors on these and other tumour cells has
led us to consider the possibility that these receptors might be
important in the growth or progression of the tumour. In the
current study, we have analysed the expression of P2U purino-
ceptors in human breast cancer cell lines. In one of these lines
(MCF-7), we have studied the effects of ATP and other purinergic
agonists on intracellular free calcium concentration ([Ca2+],) and
on cell proliferation. We have previously demonstrated prolifera-
tive effects of parathyroid hormone-related protein (PTHrP) on
MCF-7 cells (Birch et al, 1995). A synergistic interaction between
34ExtracellularATPpromotes breastcancercellgrowth 35
parathyroid hormone (PTH) and ATP on [Ca2+], has been
described in rat osteoblasts (Kaplan et al, 1995). As PTHrP binds
to the same receptor as PTH, we have studied the effects ofPTHrP,
alone and in concert with nucleotides, on MCF-7 cells.
MATERIALS AND METHODS
Cell culture
Breast cancer cell lines MCF-7, Hs578T, T47-D and SK-Br3 were
maintained in Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% fetal calf serum (FCS), 100 U ml- peni-
cillin, 100 jig ml-' streptomycin and 2 mM L-glutamine (all
reagents from Gibco). Cultures were incubated at 37°C in a fully
humidified atmosphere of7.5% carbon dioxide in air, and subcul-
tured every 3-5 days.
[Ca2+], measurement
MCF-7 cells were grown to confluence on 22-mm-diameter glass
coverslips. Following 2 h ofserum starvation, [Ca2+]i was measured.
Cells were loaded with fura-2 by incubation with fura-2
acetoxymethyl ester (5 jM) (Molecular Probes) for 20 min at 37°C
in Hepes buffer (10 mM Hepes, 121 mm sodium chloride, 4.7 mM
potassium chloride, 1.2 mm potassium hydrogen phosphate, 1.2 mM
magnesium sulphate, 2 mm calcium chloride, 5 mM sodium
hydrogen carbonate, 10 mM glucose, pH 7.2) containing 2% bovine
serum albumin (BSA). Cells were subsequently washed three times
in buffer ofthe same composition but containing 0.2% BSA.
Experiments were carried out using a photon-counting spec-
trophotometer (Cairn Instruments) on a Nikon TM Diaphot micro-
scope with a40x oil immersion lens. The cell-coated coverslip was
attached with silicone grease to form the base of a stage-mounted,
thermostatically regulated chamber maintained at 37°C. An areaof
the coverslip encompassing approximately 6-8 cells was illumi-
nated with excitation light (340 nm and 380 nm) at a rate of 32
times per second, and the emission measurements (at 510 nm)
were integrated into 1-s averages, then stored to memory. Addition
ofagonists, in Hepes bufferwith 0.2% BSA, was performed manu-
ally by Pasteur pipette, and recovery periods of at least 10 min
were allowed between agonist additions. Rmmn' Rmax and autofluo-
rescence values were obtained in situ using ionomycin, as
described by Thomas and Delaville (1991). [Ca2+] was calculated
from the ratio of fluorescence at the two excitation wavelengths,
after subtraction ofautofluorescence (Grynkiewicz et al, 1985).
RNA isolation and cDNA synthesis
Total RNA was extracted from confluent cell cultures with 4 M
guanidine thiocyanate, 0.5% sarkosyl, 0.1 M mercaptoethanol,
25 mm sodiumcitrate, pH7.0, followedby acidphenol -chloroform
extraction. RNA was treated with DNAase 1(35 U jil-) (Sigma) for
30 min to remove any residual DNA and stored as an ethanolic
precipitate at -20°C. An aliquot of 5 jig of total RNA was used as
template for first-strand cDNA synthesis in a 50-jl reaction volume
containing the following reagents: 0.5 mM dATP, dCTP, dGTP and
dTTP; 1.25 jig ofoligo(dT); 20 U RNAase inhibitor; 10 mM dithio-
threitol; 6 mm magnesium chloride; 40 mm potassium chloride;
50 mM Tris-HCI (pH 8.3); and 200 Ujgg ofRNA Moloney murine
leukaemia virus reverse transcriptase (Gibco). The reaction was
incubated at 37°C for 1 h and terminated by freezing at-200C.
Polymerase chain reaction
PCR reactions were carried out using a 50-,ul reaction volume
containing the following reagents: 1 unit of Taq DNA polymerase
(Gibco), 1 ,ul of sense and antisense primers (1 gg jil-1); 200 gM
dATP, dCTP, dGTP and dTTP (Pharmacia); 1.5 mm magnesium
chloride; 10 mm mercaptoethanol; 10 mm Tris-HCL (pH 8.3); and
2 ,ul of cDNA preparation. For P-actin and P2U purinoceptor PCR
the following conditions of denaturation, annealing and extension
were employed: 940C for 30 s; 30 cycles of 940C for 15 s, 55°C
(actin) or 60°C (P2U purinoceptor) for 30 s; 72°C for 1 min.
Primer sequences were as follows.
P2Upurinoceptor
Sense: 5'-CGTCATCCTTGTCTGTTACGTGCT
Antisense: 5'-CTACAGCCGAATGTCCTTAGTG
P-Actin
Sense: 5'-GTCGGGCGCCCCAGGCACCA
Antisense: 5'-CTCCTTAATGTCACGCACGATTTC
Southern blotting
PCR products were Southern blotted onto Zetabind hybridization
membrane according to the protocol of the manufacturer. Blots
were prehybridized in 40% formamide, 5 x SSC, 10 x Denhardt's,
1% sodium dodecyl sulphate (SDS), 200 jg ml-1 denatured
salmon sperm DNA, 200 jg tRNA for 30 min at 42°C. Blots were
probed with a 539-bp radiolabelled fragment ofP2U purinoceptor
cDNA. Membranes were washed stringently for 3 x 10 min in a
0.2 x SSC/1% SDS solution at 65°C and exposed to Kodak XAR
film with an intensifying screen.
Measurement of [3H]thymidine incorporation
MCF-7 cells were seeded into 96-well plates in DMEM/10% FCS
at a cell density of 2 x 104 cells per well and allowed to adhere
overnight in culture. The medium was then changed to 100 jl of
serum-free DMEM per well and the cells were incubated for 48 h.
(In this assay, serum-free incubation times less than 48 h resulted
in high backgrounds). A further 100 jil of serum-free medium,
containing 0.5 jiCi of [3H]thymidine together with the substance
(e.g. ATP) to be tested for effects on proliferation, was then added
to each well. Following 24 h of incubation, the medium was
removed and replaced with distilled water, the plates were frozen
and thawed to lyse the cells and the wells were harvested onto
glass-fibre filters using a cell harvester and [3H]thymidine incor-
poration measured on a scintillation counter.
Cell counting
MCF-7 cells were seeded at 2 x 104 cells per well in 0.5 ml of
DMEM/10% FCS in 24-well plates and allowed to adhere
overnight in culture. The medium was changed to serum-free
DMEM and the cells were incubated for 24 h. ATPyS and/or
PTHrP was then added at the appropriate concentration and the
plates incubated for a further 72 h. At the end of this period, the
medium was removed, the wells were washed in phosphate-
buffered saline (PBS) and 300 jil of0.25% trypsin/EDTA solution
(Gibco) was added to detach the cells. Cell numbers were counted
in a haemocytometer.
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Figure 1 Expression of P2U purinoceptors by human breast cancer cell lines.
PCR amplification of a 483-bp product from a panel of breast cancer cell line
cDNAs and corresponding Southern blot of generated PCR fragments
probed with a 539-bp fragment of the human P2U purinoceptor confirming the
specificity of amplified products. Lanes from left to right: human bone-derived
cells; MCF-7; Hs578T; SK-Br3; T47-D; water blank
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Figure 2 Elevations in [Ca2+] induced by increasing concentrations of ATP in
MCF-7 cells. ATP at the concentrations indicated was applied to groups of
6-8 fura-2-loaded MCF-7 cells. The threshold ATP concentration for
induction of a response was less than 1 gM and a maximal increase was
achieved by 5giM ATR Periods of at least 10 min were allowed between
agonist additions to ensure recovery of the cells. This plot is representative
of responses from three independent experiments from separate cell
preparations
Measurement of BUdR uptake
Uptake of bromodeoxyuridine (BUdR) was assessed by immuno-
cytochemical staining using an Amersham cell proliferation kit
(Amersham, UK). MCF-7 cells were seeded into six-well plates at a
concentration of 5 x 104 cells per well in DMEM/10% FCS and
allowed to grow untiljustsubconfluent (2-3 days). Themediumwas
then changed to serum-free and the cells incubated another 24h,
before addition of fresh serum-free medium containing BUdR
Table 1 [Ca2+],elevation in MCF-7 cells in response to P2-purinoceptor
agonists and PTHrP
Agonist [Ca2+],elevation Number of
(percentage of ATP experiments
response)
UTP 10 M 93.9± 12.5a 3
ADP 10 gM 4.9± 3.8 4
ADP 100g.M 33.0± 4.1 3
2-meSATP 10 gM 0.6 ± 3.4 3
2-meSATP 100 g,M 0.6 ± 1.5 2
ATPyS 10giM 51.2± 3.8 3
PTHrP200 ng ml-' 3.3± 0.5 2
Vehicle 2.7 ± 0.9 7
The [Ca2+]iincrease in response to nucleotides and PTHrP at the
concentrations indicated was measured in groups of 6-8 fura-2-loaded MCF-
7 cells. Data are means ± s.e. expressed as a percentage of the response to
10 giM ATP in the same cells. n is the number of results from separate cell
populations. aNot significantly different from response to ATP at P<0.05. All
other differences were significant.
labelling reagent (1:1000), and ATP or PTHrP at the appropriate
concentration. After ovemight incubation, the cells were fixed in
95% ethanol/5% acetic acid and immunostained for BUdR using
peroxidase-linked monoclonal mouse anti-BUdR and diamino-
benzidine as substrate. Thepercentage ofpositively staining nuclei
was recorded in ten random fields in each well, and five separate
wells were scored for each point.
RESULTS
MCF-7 and other breast cancer cell lines express P2U
purinoceptors
RT-PCR analysis of four human breast cancer cell lines revealed
expression ofmRNA for the P2upurinoceptor in MCF-7, Hs578T,
SK-Br3 and T47-D cells (Figure 1). Human bone cell cDNA,
which we have previously shown to express the P2u purinoceptor
(Bowler et al, 1995), was used as a positive control. All four cell
lines gave a positive PCR signal, stronger than that seen in human
bone cells, with MCF-7 cells giving a particularly strong signal.
ATP elevates [Ca2+], in MCF-7 cells
As PCR analysis gave a strong signal for the P2U purinoceptor in
the MCF-7 cell line, the response of these cells to extracellular
nucleotides was analysed. Groups of approximately 6-8 fura-
2-loaded MCF-7 cells demonstrated arise in [Ca2+]j on stimulation
with ATPin the concentration range 1-100 gM (n=6). As shown in
Figure 2, the threshold ATP concentration forinduction ofarise in
[Ca2+]i was less than 1 gM, although the response was submaximal.
A maximal [Ca2+]iincrease was recorded in response to 5 ,UM ATP.
The effects of other P2-purinoceptor agonists on [Ca2+]i were
studied in MCF-7 cells, and are recorded inTable 1, expressed as a
percentage ofthe response to a maximal concentration ofATP (10
gM) in the same cells, andcompared by Student's t-test assuming a
significance level ofP<0.05. As shown in Figure 3, UTP evoked a
rise in [Ca2+]i indistinguishable from that induced by 10 gM ATP.
The P2Y-selective agonist 2-methylthioATP (2-meSATP) failed to
increase [Ca2+], at 10 gM (Figure 3) or 100 gM. ADP was only
weakly effective; 100 gM ADP evoked a rise with an amplitude
only 33% ofthat seen in response to 10 iM ATP in the se cells.
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Table 2 Numbers of MCF-7 cells staining positively for BUdR uptake
following stimulation with ATPyS or PTHrP
Agonist Positive cells %
Control 14.84 + 1.22
FCS 23.59 + 1 .45*
ATPyS 1 ,UM 14.07 ± 0.87
ATPyS 10 ztM 23.65 + 0.76*
PTHrP 100 ng ml-' 16.76 ± 1.65
PTHrP 100 ng ml-' + ATPyS 10 gM 24.17+ 1.96*
MCF-7 cells were seeded into six-well plates at a concentration of 5x104
cells per well in DMEM/10% FCS and allowed to grow until just subconfluent
(2-3 days). The medium was then changed to serum-free and the cells
incubated another 24 h, before addition of fresh serum-free medium
containing BUdR and ATP-yS or PTHrP at the concentrations indicated. After
overnight incubation, the cells were fixed and immunostained for BUdR
uptake. The percentage of positively staining nuclei was recorded in ten
random fields in each well, and five separate wells were scored for each
point. The percentage of positively staining nuclei is shown as a mean + s.e.
of all fields.
Degradation of ATP precludes its use in proliferation studies
that require incubation over long periods. Instead the slowly
hydrolysed phosphorothioate ATP analogue ATPyS was used in
these studies. The ability of this nucleotide to elevate [Ca2+], was
therefore studied. ATPyS (10 gM) elicited a rise in [Ca2+], equiva-
lent to 51% ofthat induced by 10 gM ATP (Table 1).
PTHrP, which we have previously shown to provide a prolifera-
tive stimulus for MCF-7 cells (Birch et al, 1995), did not induce
any increase in [Ca2+], (Figure 4).
ATPyS stimulates proliferation of MCF-7 cells
To investigate the potential effects ofATP on proliferation, ATPyS
was used, as indicated above. Proliferation was analysed by three
methods, uptake of [3H]thymidine, incorporation of BUdR and
counting of total cell numbers. By all three methods, micromolar
concentrations of ATPyS were shown to provide a proliferative
stimulus for MCF-7 cells. Thymidine incorporation by serum-
starved MCF-7 cells was approximately doubled in the presence of
5 gM ATPyS compared with controls (Figure 5). Increasing the
concentration of ATPyS to 50 gM or 500 gM did not produce any
further rise above that seen with 5 ,UM ATPyS. Similarly, the
numbers of nuclei staining positively for BUdR uptake more than
doubled in the presence of 10gM ATPyS (Table 2). When total cell
numbers were counted, a similarpattern emerged. Whereas serum-
starved MCF-7 cells showed little or no increase in cell number
after a further 3 days in serum-free medium, the addition ofATPyS
(10 gM) to the medium on a daily basis resulted in a doubling of
cell numbers after 3 days (Figure 6). PTHrP also increased cell
numbers, and when ATPyS (10 ,UM) and PTHrP (100 ng ml-') were
applied together, an additive effect was seen in the cell-counting
assay, although not in the BUdR assay. This suggests that ATP
(ATPyS) and PTHrP may act via different pathways in MCF-7
cells, which is consistent with the finding shown in Figure 4,
where PTHrP, unlike ATP, did not evoke a rise in [Ca2+]i.
DISCUSSION
In this study we have demonstrated the presence of mRNA for the
P2Upurinoceptor in human breast cancer cell lines and have shown
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Figure 3 Nucleotide-induced elevations in [Ca2+] in MCF-7 cells. Fura-2-
loaded MCF-7 cells responded to extracellular ATP (10 gM) and UTP (10 gM)
with rises in [Ca2'j of similar amplitude. Application of ADP and 2-meSATP,
for the periods indicated, failed to elevate [Ca2j. This trace is representative
of responses from three cell preparations
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Figure 4 PTHrP does not elevate [Ca2+] in MCF-7 cells. Application of
PTHrP (200 ng ml-') to 6-8 fura-2-loaded MCF-7 cells had no effect on
[Ca2j]. The application of ATP before and after addition of PTHrP resulted in
a rise in [Ca2+l,. This result is typical of two independent experiments from
separate cell preparations
that ATP elevates [Ca2+]i in MCF-7 cells. The possibility that
MCF-7 cells additionally express other P2-purinoceptor subtypes
was investigated by studying the effects of a range of nucleotides.
Thus, the ineffectiveness of 2-meSATP and ADP to induce [Ca2+]i
rises in MCF-7 cells argues against the expression ofP2Y(P2Y,) or
P2T (P2Y3) purinoceptors, respectively, for which these nucleotides
are agonists (Barnard et al, 1994). The P2U purinoceptor is known
to be activated equipotently by ATP and UTP, and the [Ca2+]i rises
induced by these two nucleotides were indistinguishable, arguing
against the expression of an additional ATP- or UTP-sensitive
receptor. These data are consistent with MCF-7 cells expressing a
single P2-purinoceptor subtype, the P2u receptor.
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Figure 5 Incorporation of [3H] thymidine by MCF-7 cells in response to
ATPyS and PTHrR MCF-7 cells were seeded into 96-well plates in
DMEM/10% FCS at a cell density of 2x104 cells per well and allowed to
adhere overnight in culture. The cells were then incubated in 100 ,ul of
serum-free medium for 48 h, and a further 100 gl of serum-free medium was
added, containing ATPyS (5-500 gM) and 0.5 1Ci of [3H]thymidine. After 24 h
incubation, the cells were harvested and [3H]thymidine incorporation
measured on a scintillation counter. All data represented as mean ± s.e.
(n = 6). Asterisk denotes significance at P<0.05
Elevation of[Ca2+], occurs as an initial response to receptor acti-
vation, resulting in downstream effects on cellular differentiation
and proliferation. Our results suggest that one of the consequences
ofP2U purinoceptor activation in breast cancer cells is stimulation of
proliferation. Proliferation of MCF-7 cells was induced by 10gM
ATPyS, a concentration sufficient to induce P2U purinoceptor-
mediated increases in [Ca2+]i shown here, and in a previous study
that characterized the P2U purinoceptor cloned from NG108-15
mouse neuroblastoma-rat glioma hybrid cells (Erb et al, 1993).
ATPyS was found to stimulate proliferation of MCF-7 cells by all
three of the distinct techniques used to measure cell proliferation.
A similar proliferative effect ofATP has been noted on the human
ovarian cancer cell lines OVCAR-3 (Popper and Batra, 1993) and
SKOV-3 (Batra and Fadeel, 1994), at concentrations of ATP that
maximally elevate [Ca2+]i. At higher concentrations, the mitogenic
effect of ATP seen in several transformed and cancerous cells is
superseded by a growth-inhibitory effect. Thus, ATP-induced inhi-
bition of cell growth in SKOV-3 cells was achieved by 100 gM to
1 mm ATP (Batra and Fadeel, 1994). Similarly high concentrations
of ATP were reported to induce growth inhibition in two breast
cancer cell lines, T47-D (Spungin and Friedberg, 1993) and that
usedhere, MCF-7 (Vandewalle etal, 1994). The mechanismunder-
lying this inhibition is not fully understood. Some investigators
have attributed inhibition to adenosine following the sequential
dephosphorylation ofATP (Spungin and Friedberg, 1993; Lasso de
la Vega et al, 1994), whereas others have invokedP2Z purinoceptor-
mediated cell permeabilization (Rapaport, 1990; Dubyak and El-
Moatassim, 1993). Considering the high concentrations of ATP
required to achieve this effect, its physiological relevance is ques-
tionable. We have not observed any inhibition of cell growth in
response to ATPyS at concentrations up to 100gM, which may be a
result ofusing this slowly hydrolysable analogue ofATP.
The response oftumour cells to growth factors and other agents
is dependent on the range ofreceptors expressed by the cells. The
expression ofP2U purinoceptors by breast cancer cells indicates that
ATP must be considered as a potential regulatory factor in cancer
cell growth. In concert with other factors, the mitogenic stimulus
provided by ATP could be sufficient to drive tumour growth or
progression in vivo. One such factor could be PTHrP, as PTHrP
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Figure 6 Cellular proliferation of MCF-7 cells in response to PTHrP and
ATPyS assessed by direct cell counting. MCF-7 cells were seeded at 2x1 04
cells per well in 24-well plates in DIVEM/10% FCS, serum starved and
stimulated with ATP-yS (10 gim) or PTHrP (100 ng mi-') in DMEM for 72 h.
The cells were then removed by trypsinization and counted in a
haemocytometer. Cell numbers are shown as mean cells per well of six
separate wells ± s.e.
induced proliferation in MCF-7 cells in a manner similar to ATP.
When ATPyS and PTHrP were applied together, proliferation was
greater than seen with either agonist alone (in the cell-counting
assay), although the effects were at best additive rather than syner-
gistic. The demonstration that PTHrP is ineffective in eliciting a
rise in [Catls] in contrast to ATP or ATPyS is suggestive of ATP
stimulating proliferation via a different pathway to PTHrP. Both of
these molecules are likely to be encountered by breast tumour cells
in the microenvironment in vivo; PTHrP is commonly expressed in
breast tumours (Vargas et al, 1992), whereas potential sources of
high local ATP concentrations would include any condition in
which cells are being lysed, including ischaemia and necrosis,
inflammation or specific lysis by cytotoxic or NK cells.
These dataimplicate nucleotides and theirreceptors eitheralone
or in combination with other tumour-stimulatory factors as
possible regulators of tumour cell growth and as potential thera-
peutic targets for inhibiting tumour progression.
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